文献速递咽喉与嗓音

痉挛性发声障碍患者对肉毒毒素注射疼痛的感知

Spasmodic Dysphonia Patients' Perception of Pain with Botulinum Toxin Injections.
PubMed 文献 · Laryngoscope · 2023-07-06

前瞻性队列研究纳入119例成人内收型痉挛性发声障碍患者,在2022年3月至7月接受喉部肉毒毒素注射,评估预测疼痛与注射后疼痛及影响因素。注射耐受良好,疼痛评分低;双侧注射者SF-MPQ评分显著高于单侧注射者,非专业嗓音使用者注射后VAS较高。

要点

  • 肉毒毒素注射耐受良好,SF-MPQ报告轻度疼痛(4.12±4.05/45)。
  • 双侧注射者SF-MPQ评分显著高于单侧注射者(5.19±4.66 vs 3.30±3.30,p=0.012)。
  • 非专业嗓音使用者注射后VAS评分较高(p=0.008)。

核心结论

  • 肉毒毒素注射耐受良好且疼痛评分低,与较高预测或实际疼痛相关的因素包括双侧与单侧注射、专业嗓音使用者身份及较高的VHI-10。

研究设计与样本

  • 前瞻性队列研究,纳入2022年3月至7月就诊于三级喉科诊所接受肉毒毒素注射的成人内收型痉挛性发声障碍患者119例(63±14岁,26%男性)。

主要发现

  • SF-MPQ报告轻度疼痛(4.12±4.05/45),疼痛强度为无至轻度(0.70±0.89/5)。
  • 双侧注射者SF-MPQ评分(5.19±4.66)显著高于单侧注射者(3.30±3.30)(p=0.012)。
  • VAS从术前28.9±24.6 mm降至术后24.5±22.3 mm(p<0.001)。
  • 多因素回归中,接受双侧注射显著(p<0.05)贡献于预测较高术前VAS的模型(p=0.013)。
  • 双侧注射(p<0.05)和较高VHI-10(p<0.05)贡献于预测较高SF-MPQ总分(p=0.001)和情感SF-MPQ评分(p=0.001)的模型。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate spasmodic dysphonia patients' perception of pain associated with laryngeal botulinum toxin (BTX) injections and to determine factors associated with higher pain scores relative to other included patients. METHODS: Prospective cohort study. Adult patients with adductor spasmodic dysphonia that presented to a tertiary laryngology practice for BTX injections were recruited from March to July 2022. Patients completed the visual analog scale (VAS) pre-procedure to quantify predicted pain. Ten minutes post-procedure they completed VAS and the short form McGill Pain Questionnaire (SF-MPQ). Factors that may affect pain were extracted from charts. Descriptive statistics, univariate, and multivariate analyses were conducted (alpha = 0.05). RESULTS: One hundred and nineteen patients were included (63 ± 14 yo, 26% Male). SF-MPQ reported mild pain (4.12 ± 4.05 out of 45) with a pain intensity of none to mild (0.70 ± 0.89 out of 5). Bilateral injections yielded significantly higher SF-MPQ scores (5.19 ± 4.66) than unilateral injections (3.30 ± 3.30) (p = 0.012). There was a significant VAS reduction from pre 28.9 ± 24.6 mm (out of 10 mm) to post 24.5 ± 22.3 (p < 0.001). On multiple regression analyses, receiving a bilateral injection significantly (p < 0.05) contributed to a model that predicted higher pre-VAS (p = 0.013). Bilateral injections (p < 0.05) and higher VHI-10 (p < 0.05) contributed to a model that predicted higher total SF-MPQ (p = 0.001) and affective SF-MPQ (p = 0.001) scores. Not being a professional voice user (PVU) significantly (p < 0.05) contributed to a model that predicted higher post-VAS (p = 0.008) scores. CONCLUSIONS: BTX injections were well tolerated with low pain scores. Factors associated with higher relative predicted or experienced pain included bilateral versus unilateral injection, PVU status, and higher VHI-10. LEVEL OF EVIDENCE: 4 Laryngoscope, 134:240-246, 2024.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Heffernan A, Hu A. Spasmodic Dysphonia Patients' Perception of Pain with Botulinum Toxin Injections. Laryngoscope. 2023. PMID: 37409790. doi:10.1002/lary.30864

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。